Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary EDAP Reports Second Quarter 2013 Results
Received CE mark for innovative robotic HIFU device Focal One ® Eliminated all outstanding long-term debt and strengthened financial profile Publication of long-term study reporting 10 year cancer-specific survival and metastatic-free survival rates for prostate cancer patients treated with
View HTML
Toggle Summary CORRECTING AND REPLACING -- EDAP to Present at Rodman & Renshaw Annual Global Investment Conference, 15th Annual Healthcare Conference Sponsored by H.C. Wainwright & Co.
LYON, France , Aug. 26, 2013 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by EDAP TMS SA (Nasdaq:EDAP), please note that the presentation time should be 10:50 am ET — 11:15 am ET , rather than 10:25 am ET — 10:50 am ET as originally stated.
View HTML
Toggle Summary EDAP Schedules Webcast and Conference Call for Second Quarter 2013 Results
LYON, France , Aug. 13, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its second quarter 2013 results announcement, which will take place on Wednesday, August 28, 2013 , before the opening of the market.
View HTML
Toggle Summary EDAP Granted European Market Clearance for Focal.One(R)
Positions Focal.One Robotic HIFU Device for Commercialization
View HTML
Toggle Summary EDAP Fully Redeems $8.0 Million Long-Term Debt
Ablatherm-HIFU PMA Application Process Continues to Advance
View HTML
Toggle Summary EDAP Significantly Strengthens Financial Profile
Closes $12.0 Million Placement to Fully Redeem $8.0 Million Long-Term Debt Positions Company to Invest in Expansion of U.S. Operations LYON, France , May 29, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), a global leader in therapeutic ultrasound, outlined today the strengthening of its
View HTML
Toggle Summary EDAP to Raise $12 Million in Registered Direct Offering
LYON, France , May 21, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), a global leader in therapeutic ultrasound, announced that it has entered into definitive agreements with certain institutional investors for a registered direct placement of $12 million of ordinary shares in the form of
View HTML
Toggle Summary EDAP's Ablatherm-HIFU Demonstrates Long Term Efficacy, Durability and Reproducibility With Prospective Fourteen -Year Study
Third Long Term Study Published in 2013 Validates Ablatherm-HIFU as First Line Treatment of Prostate Cancer
View HTML
Toggle Summary EDAP Reports 23% Increase in First Quarter 2013 Revenues
First quarter 2013 revenue rose 23% to EUR 5.9 million ( USD 7.8 million ) Continuing US investments in both FDA regulatory process and US operations Great momentum and success achieved at two of the world major urology congresses for EDAP's advanced technologies Publication of two independent
View HTML
Toggle Summary EDAP's Ablatherm-HIFU Receives Two Best Poster Awards at 2013 American Urological Association Annual Meeting
Four Scientific Sessions Highlighted HIFU for Treatment of Prostate Cancer HIFU Featured in Plenary Lecture and Two Moderated Posters at Engineering and Urology Society Meeting Significant Interest in both HIFU and ESWL Technologies at EDAP Booth LYON, France , May 14, 2013 (GLOBE NEWSWIRE) -- EDAP
View HTML